221 related articles for article (PubMed ID: 34971481)
21. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.
Bu R; Siraj AK; Divya SP; Kong Y; Parvathareddy SK; Al-Rasheed M; Al-Obaisi KAS; Victoria IG; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
Int J Cancer; 2018 May; 142(10):2028-2039. PubMed ID: 29266240
[TBL] [Abstract][Full Text] [Related]
22. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
23.
Arantes LMRB; Cruvinel-Carloni A; de Carvalho AC; Sorroche BP; Carvalho AL; Scapulatempo-Neto C; Reis RM
Front Oncol; 2020; 10():1275. PubMed ID: 32850388
[No Abstract] [Full Text] [Related]
24. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
[TBL] [Abstract][Full Text] [Related]
25. TERT promoter mutations in telomere biology.
Heidenreich B; Kumar R
Mutat Res Rev Mutat Res; 2017; 771():15-31. PubMed ID: 28342451
[TBL] [Abstract][Full Text] [Related]
26. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
[TBL] [Abstract][Full Text] [Related]
27.
Tanaka A; Matsuse M; Saenko V; Nakao T; Yamanouchi K; Sakimura C; Yano H; Nishihara E; Hirokawa M; Suzuki K; Miyauchi A; Eguchi S; Yoshiura KI; Yamashita S; Nagayasu T; Mitsutake N
Thyroid; 2019 Aug; 29(8):1105-1114. PubMed ID: 31286848
[No Abstract] [Full Text] [Related]
28. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
[TBL] [Abstract][Full Text] [Related]
29. TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma.
Brügger F; Dettmer MS; Neuenschwander M; Perren A; Marinoni I; Hewer E
J Neuropathol Exp Neurol; 2017 Jan; 76(1):61-66. PubMed ID: 28040793
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
31. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
32. Advances in Detecting Low Prevalence Somatic
da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
[TBL] [Abstract][Full Text] [Related]
33. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E.
Song YS; Park YJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):515-525. PubMed ID: 32981294
[TBL] [Abstract][Full Text] [Related]
35. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
[TBL] [Abstract][Full Text] [Related]
37. Telomere length assessment and molecular characterization of TERT gene promoter in periampullary carcinomas.
Gregório C; Thakur S; Camara Rivero R; Márcia Dos Santos Machado S; Cuenin C; Carreira C; White V; Cree IA; Vukojevic K; Glavina Durdov M; Bersch Osvaldt A; Ashton-Prolla P; Herceg Z; Talukdar FR
Gene; 2023 Jul; 873():147460. PubMed ID: 37150235
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
de Graaff MA; Yu JS; Beird HC; Ingram DR; Nguyen T; Juehui Liu J; Bolshakov S; Szuhai K; Åman P; Torres KE; Lev D; Nielsen TO; Bovée JV; Lazar AJ; Somaiah N
Lab Invest; 2016 Aug; 96(8):885-94. PubMed ID: 27270875
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Killela PJ; Reitman ZJ; Jiao Y; Bettegowda C; Agrawal N; Diaz LA; Friedman AH; Friedman H; Gallia GL; Giovanella BC; Grollman AP; He TC; He Y; Hruban RH; Jallo GI; Mandahl N; Meeker AK; Mertens F; Netto GJ; Rasheed BA; Riggins GJ; Rosenquist TA; Schiffman M; Shih IeM; Theodorescu D; Torbenson MS; Velculescu VE; Wang TL; Wentzensen N; Wood LD; Zhang M; McLendon RE; Bigner DD; Kinzler KW; Vogelstein B; Papadopoulos N; Yan H
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6021-6. PubMed ID: 23530248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
